Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Shares Outstanding (Diluted Average) (2016 - 2025)

Lisata Therapeutics filings provide 6 years of Shares Outstanding (Diluted Average) readings, the most recent being $8.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 4.3% year-over-year to $8.7 million, compared with a TTM value of $8.7 million through Dec 2025, up 4.3%, and an annual FY2025 reading of $8.7 million, up 4.3% over the prior year.
  • Shares Outstanding (Diluted Average) hit $8.7 million in Q4 2025 for Lisata Therapeutics, down from $8.7 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $8.7 million in Q3 2025, with the low at $8.0 million in Q1 2023.
  • Median Shares Outstanding (Diluted Average) over the past 3 years was $8.3 million (2024), compared with a mean of $8.3 million.
  • The sharpest move saw Shares Outstanding (Diluted Average) rose 2.04% in 2024, then rose 5.19% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $8.1 million in 2023, then grew by 3.17% to $8.3 million in 2024, then grew by 4.3% to $8.7 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $8.7 million, $8.7 million, and $8.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.